NCT02259777已完成1 期
Influence of Food on the Bioavailability of 80 mg Telmisartan/10 mg Amlodipine Fixed Dose Combination in Healthy Male and Female Volunteers. An Open-label, Randomised, Single-dose, Two Period, Crossover Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 主要终点
- Area under the concentration-time curve of the analyte in plasma over the time interval from zero extrapolated to infinity (AUC0-∞)
研究概览
简要总结
Study to investigate the effect of food intake on the bioavailability of a fixed dose combination of 80 mg telmisartan / 10 mg amlodipine following a high fat breakfast
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy males and females according to the following criteria:
- •Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests
- •Age ≥18 and Age ≤55 years
- •BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation
排除标准
- •Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
- •Any evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Surgery of the gastrointestinal tract (except appendectomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- •Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial except for oral contraceptives as well as ovary and thyroid hormone replacement
- •Use of drugs which might reasonably influence the results of the trial (especially unspecific inducing agents like St.John´s wort (Hypericum perforatum) or inhibitors like cimetidine) or that prolong the QT/corrected QT interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- •Participation in another trial with an investigational drug within one month prior to administration or during the trial
- •Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- •Inability to refrain from smoking during 24 hours prior to dosing and during the trial
- •Alcohol abuse or inability to stop alcoholic beverages for 24 hours prior to dosing and during the trial
- •Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- •Excessive physical activities (within one week prior to administration or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of trial site
- •Any history of relevant low blood pressure
- •Supine blood pressure at screening of systolic <110 mm Hg and diastolic <60 mm Hg
- •History of urticaria
- •History of angioneurotic edema
- •Fructose intolerance
- •For female subjects:
- •Pregnancy / positive pregnancy test, or planning to become pregnant during the study or within 1 month of study completion
- •No adequate contraception during the study and until 1 month of study completion, i.e. implants, injectables, combined oral contraceptives, IUD [intrauterine device], sexual abstinence (for at least 1 month prior to enrolment), vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or surgical sterilisation (incl. hysterectomy). Females, who have not a vasectomised partner, are not sexually abstinent or surgically sterile will be asked to additionally use barrier contraception methods (e.g. condom, diaphragm with spermicide)
- •Lactation period
研究组 & 干预措施
Telmisartan/Amlodipine, fasted
Active Comparator
干预措施: Telmisartan/Amlodipine (Drug)
Telmisartan/Amlodipine, fed
Experimental
干预措施: Telmisartan/Amlodipine (Drug)
Telmisartan/Amlodipine, fed
Experimental
干预措施: high fat, high caloric meal (Other)
结局指标
主要结局
Area under the concentration-time curve of the analyte in plasma over the time interval from zero extrapolated to infinity (AUC0-∞)
时间窗: up to 168 hours after drug administration
Maximum measured concentration of the analyte in plasma (Cmax)
时间窗: up to 168 hours after drug administration
次要结局
- Mean residence time in the body after po administration (MRTpo)(up to 168 hours after drug administration)
- Apparent plasma clearance after p.o. administration (CL/F)(up to 168 hours after drug administration)
- Number of subjects with adverse events(up to 65 days)
- Terminal half-life in plasma (t1/2)(up to 168 hours after drug administration)
- Assessment of tolerability by investigator on a 4-point scale(day 8 after administration of study drug)
- Area under the concentration-time curve of telmisartan and amlodipine in plasma over the time interval zero to the last quantifiable data point (AUC0-tz)(up to 168 hours after drug administration)
- Terminal rate constant in plasma (λz)(up to 168 hours after drug administration)
- Time from dosing to the maximum concentration in plasma (tmax)(up to 168 hours after drug administration)
- Apparent volume of distribution during the terminal phase λz after p.o. administration (Vz/F)(up to 168 hours after drug administration)
研究者
相似试验
已完成
1 期
Influence of Food on the Bioavailability of Telmisartan / Ramipril Fixed Dose Combination in Healthy Male and Female VolunteersHealthyNCT02214966Boehringer Ingelheim42
已完成
1 期
Influence of Food on the Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Japanese Male VolunteersHealthyNCT02261064Boehringer Ingelheim32
已完成
1 期
A Study of LY2801653 in Healthy Participants Who Are Not Able to Have ChildrenHealthyNCT02370485Eli Lilly and Company23
已完成
1 期
Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male VolunteersHealthyNCT02172209Boehringer Ingelheim14
已完成
1 期
Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without FoodHealthyNCT01286571Boehringer Ingelheim14